Revvity Inc
RVTY
Company Profile
Business description
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Contact
77 4th Avenue
WalthamMA02451
USAT: +1 781 663-6900
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
11,000
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
I catch up with Shane Ponraj after an eventful reporting season for healthcare major CSL.
stocks
This ASX stock’s bubble has well and truly burst
Pandemic related tailwinds are a distant memory for Reece, which looks set to face more competition in Australia.
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,218.00 | 10.50 | -0.11% |
| CAC 40 | 7,709.81 | 133.23 | -1.70% |
| DAX 40 | 24,152.87 | 120.25 | -0.50% |
| Dow JONES (US) | 45,418.07 | 135.60 | 0.30% |
| FTSE 100 | 9,265.80 | 55.60 | -0.60% |
| HKSE | 25,542.52 | 17.60 | 0.07% |
| NASDAQ | 21,544.27 | 94.98 | 0.44% |
| Nikkei 225 | 42,588.27 | 193.87 | 0.46% |
| NZX 50 Index | 12,900.88 | 57.10 | -0.44% |
| S&P 500 | 6,465.94 | 26.62 | 0.41% |
| S&P/ASX 200 | 8,950.70 | 10.50 | -0.12% |
| SSE Composite Index | 3,881.07 | 12.69 | 0.33% |